Generic Bridion Availability
BRIDION (sugammadex sodium - solution;intravenous)
Manufacturer: ORGANON SUB MERCK
Approval date: December 15, 2015
Strength(s): EQ 200MG BASE/2ML (EQ 100MG BASE/ML), EQ 500MG BASE/5ML (EQ 100MG BASE/ML) [RLD]
Has a generic version of Bridion been approved?
No. There is currently no therapeutically equivalent version of Bridion available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bridion. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
Issued: September 27, 2005
Inventor(s): Zhang; Mingqiang & Palin; Ronald & Bennett; David Jonathan
Assignee(s): Akzo Nobel N.V.
Disclosed is a 6-mercapto-cyclodextrin derivative having a general formula (I, ) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C1-6) alkylene, optionally substituted with 1-3 OH groups, or (CH2)o-phenylene-CH2)p—; o and p are independently 0-4; X is COOH, CONHR3, NHCOR2, SO2OH, PO(OH)2, O(CH2—CH2—O)q—H, OH or tetrazol-5-yl: R2 is H or (C1-3)alkyl; R2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block.Patent expiration dates:
- January 27, 2021✓
- January 27, 2021
Use of chemical chelators as reversal agents for drug-induced neuromuscular block
Issued: September 4, 2007
Inventor(s): Bom; Antonius Helena Adolf & Muir; Alan William & Rees; David
Assignee(s): Organon N.V.
The invention relates to the use of chemical chelators for the preparation of a medicament for the reversal of drug-induced neuromuscular block, to a kit for providing neuromuscular block and its reversal, and to cyclophane derivatives having general formula (A) wherein R is (a), (b) or (c); or general formula (B) wherein X is (a), (b) or (d), or a pharmaceutically acceptable salt thereof.Patent expiration dates:
- August 7, 2020✓
- August 7, 2020
6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
Issued: January 28, 2014
Assignee(s): Merck Sharp & Dohme B.V.
Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH2)o-phenylene-(CH2)p—; o and p are independently 0-4; X is COOH, CONHR1, NHCOR2, SO2OH, PO(OH)2, O(CH2—CH2—O)q—H, OH or tetrazol-5-yl; R1 is H or (C1-3)alkyl; R2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block.Patent expiration dates:
- January 27, 2021✓✓✓
- January 27, 2021
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- December 15, 2020 - NEW CHEMICAL ENTITY
More about Bridion (sugammadex)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|